Jerry R. Youkey, M.D.
Jerry R. Youkey, M.D., joined Greenville Health System (GHS) in 1998, and currently serves as GHS Executive Vice President and Chief Academic Officer, reporting to the CEO. GHS is an eight-campus integrated delivery system with 1,756 beds, employing approximately 14,000 employees and 1,000 medical doctors. Since 2011, Dr. Youkey has additionally served as Founding Dean of University of South Carolina School of Medicine Greenville and in 2015, was appointed University of South Carolina Associate provost for Health Sciences Greenville.
Dr. Youkey served a rotating internship and general surgery residency at William Beaumont Army Medical Center, El Paso, TX, and a fellowship in peripheral vascular surgery at Walter Reed Army Medical Center, Washington D.C. He also served in the U.S. Army and was honorably discharged in August 1984, after attaining the rank of Colonel, Medical Corps. Dr. Youkey served as Chief, Department of Surgery and Director, Peripheral Vascular Surgery Fellowship Program at Geisinger Medical Center, Danville, PA, prior to coming to Greenville. He is certified by the American Board of Surgery in general vascular surgery.
He is widely published in his specialty field of general vascular surgery, having authored books, abstracts and journal articles. He holds the academic appointment of Professor and Associate Dean at the University of South Carolina, Columbia, SC. He received his B.A. from Stanford University, Palo Alto, CA, his medical degree from the Medical College of Wisconsin, Milwaukee, WI and is a member of numerous professional societies and organizations.
Dale Zajicek, Board Member
Mr. Zajicek has over 37 years of experience in the pharmaceutical and biotech industry. In 2015 he retired as President of BioVectra, Inc., located in Charlottetown, Prince Edward Island, Canada, and was with this company since 1995. Following his promotion to Chief Operating Officer in 2005, he has been responsible for significant growth of the firm’s contract manufacturing and drug development efforts, with the firm filing numerous Drug Master Files (DMF), Investigational New Drug applications (IND), and supported the New Drug Applications for numerous clients.
Mr. Zajicek successfully led BioVectra to the development of generic docetaxel, and obtained first to file status for this $1 billion annual sales oncology drug. BioVectra successfully partnered the product with Sandoz for the US market, and other marketing firms for markets in Canada, Europe, Middle East, North Africa, and South America. BioVectra is engaged with clients and partners on several clinical phase, pre-commercial, and commercial opportunities. Under Mr. Zajicek’s leadership, BioVectra has developed capabilities in microbial fermentation for protein-based and small molecule drugs, as well as combining biotech processing with synthetic capabilities to perform unique chemistries and conjugations of large to small molecules.
Prior to joining BioVectra, Mr. Zajicek held positions in manufacturing operations, engineering, research and product development, and business development at G. D. Searle and The NutraSweet Company.
He holds a BS in Chemical Engineering from Illinois Institute of Technology and a BS in Business Administration from Elmhurst College. He has an in-depth working knowledge of the process development and commercial processing.
Joseph Podolski, Board Member
Mr. Podolski has over 37 years experience in the pharmaceutical and biotech industry. He is the former President and CEO of Repros Therapeutics (formerly Zonagen) and has been with this company since 1989. Following his promotion to President and CEO in 1992, he was instrumental in taking Repros public the following year after he redirected the efforts of the company from animal health into human reproductive health.
Mr. Podolski retired from both Repros Therapeutics and Oncolix in 2017.